Compare Hinge Health Inc. Class A Common Stock (HNGE) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs MasTec Inc — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while MasTec Inc trades at $191.9 (market cap $16.55B). The key difference: MasTec Inc is the larger of the two by market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and MasTec Inc for 25 Days on average.
| HNGE | MTZ | |
|---|---|---|
Market Cap | $8.48B | $16.55B |
Volume | 879,799 | 1,530,865 |
Sector | Health | Industrials |
52-Week High | $105.14 | $437.51 |
52-Week Low | $31.17 | $190.08 |
Typical Hold Time | 0 Days | 25 Days |
Enterprise Value | $8.10B | $19.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
MasTec (MTZ) trades at $206.12, down 0.35% on the day, with technical indicators showing bearish momentum below key moving averages. The company reported strong revenue growth from $14.3B in 2025 to $16.1B in 2026, with net income improving to $494M. Recent news highlights MTZ's record $21.4B backlog and positioning in AI infrastructure and power delivery markets, though cash flow volatility and premium valuation pose challenges.
Wall Street maintains strong bullish sentiment with 89% buy ratings and a $403.92 consensus price target, representing 96% upside potential. Key opportunities include infrastructure investment cycles and data center expansion, while risks include execution challenges, communications segment softness, and elevated P/E ratio of 32.8x.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
